Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.(I).2 - JUNIPER PHARMACEUTICALS INC | jnp-ex312_200.htm |
| EX-32.2 - EX-32.2 - JUNIPER PHARMACEUTICALS INC | jnp-ex322_14.htm |
| EX-32.1 - EX-32.1 - JUNIPER PHARMACEUTICALS INC | jnp-ex321_10.htm |
| EX-31.1 - EX-31.(I).1 - JUNIPER PHARMACEUTICALS INC | jnp-ex311_201.htm |
| EX-23.2 - EX-23.2 - JUNIPER PHARMACEUTICALS INC | jnp-ex232_203.htm |
| EX-21 - EX-21 - JUNIPER PHARMACEUTICALS INC | jnp-ex21_264.htm |
| 10-K - 10-K - JUNIPER PHARMACEUTICALS INC | jnp-10k_20171231.htm |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Forms S‑3 (Nos. 333-206928, 333-169599, 333-75275, 333-155530, 333-125671,333-132803, 333-140107, 333-37976 and 333-38230) and Forms S-8 (Nos. 333-34079, 333-63470, 333-116072, 333-152008, 333-188647, 333-205723 and 333-213433) of Juniper Pharmaceuticals, Inc. of our report dated March 9, 2018 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 9, 2018